ストックスクリーナーアプリを入手
60.63
0.25%
0.20
前日終値:
$60.43
開ける：
$60.43
24時間の取引高:
1.20M
Relative Volume:
0.50
時価総額：
$11.66B
収益：
$2.95B
当期純損益:
$523.88M
株価収益率:
22.54
EPS:
2.69
ネットキャッシュフロー:
$620.18M
1週間 パフォーマンス:
-0.87%
1か月 パフォーマンス:
+6.00%
6か月 パフォーマンス:
+4.86%
1年 パフォーマンス:
-14.91%
1日の値動き範囲:
$59.72
$61.20
1週間の範囲:
$58.50
$63.21
52週間の値動き範囲:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
名前
Biomarin Pharmaceutical Inc
セクター
電話
(415) 506-6700
住所
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
60.61 | 11.62B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.68 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.76 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
725.75 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.55 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.43 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-20 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | ダウングレード | Stifel | Buy → Hold |
| 2025-09-08 | 開始されました | H.C. Wainwright | Neutral |
| 2025-09-03 | 開始されました | Raymond James | Outperform |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-02-24 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-30 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-20 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 開始されました | Evercore ISI | Outperform |
| 2023-11-15 | 開始されました | Wells Fargo | Overweight |
| 2023-10-23 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 開始されました | Raymond James | Mkt Perform |
| 2023-09-18 | 開始されました | UBS | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Perform |
| 2023-07-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-03-21 | 開始されました | Bernstein | Underperform |
| 2023-02-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 開始されました | Citigroup | Neutral |
| 2023-01-30 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2022-10-31 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 再開されました | Wedbush | Neutral |
| 2022-04-25 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 再開されました | Jefferies | Buy |
| 2021-09-09 | アップグレード | Stifel | Hold → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-04 | 再開されました | Guggenheim | Buy |
| 2021-03-01 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-08-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-08-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2020-08-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | ダウングレード | Stifel | Buy → Hold |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 繰り返されました | Citigroup | Buy |
| 2020-01-28 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-27 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-24 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-04-09 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 繰り返されました | Stifel | Buy |
| 2018-08-03 | 繰り返されました | Stifel | Buy |
すべてを表示
Biomarin Pharmaceutical Inc (BMRN) 最新ニュース
Skeletal Dysplasia Market - GlobeNewswire Inc.
Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight - Bolsamania
Elo Mutual Pension Insurance Co Boosts BioMarin Pharmaceutical Holdings - National Today
Elo Mutual Pension Insurance Co Purchases 22,851 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Barclays raises BioMarin stock price target to $105 on acquisition By Investing.com - Investing.com UK
Amicus Therapeutics shareholders approve acquisition by BioMarin Pharmaceutical - Investing.com
Shareholders back Amicus (NASDAQ: FOLD) sale to BioMarin Pharmaceutical - Stock Titan
The kids are alright: Old drug from BioMarin scores key win in teensSan Francisco Business Times - The Business Journals
Barclays raises BioMarin stock price target to $105 on acquisition - Investing.com
BioMarin Receives FDA Approval for PALYNZIQ in Pediatric Patients - Intellectia AI
Truist reiterates Buy on BioMarin stock amid new competition - Investing.com
BioMarin stock price target raised to $105 by Freedom Capital on margin outlook - Investing.com Nigeria
Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel - Fierce Pharma
Cantor Fitzgerald reiterates Overweight on BioMarin stock at $85 - Investing.com
BioMarin Pharmaceutical Inc. $BMRN Holdings Cut by Rafferty Asset Management LLC - MarketBeat
BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients - Benzinga
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Envestnet Asset Management Inc. - MarketBeat
2 Reasons to Like BMRN (and 1 Not So Much) - Finviz
Canaccord Lifts PT on BioMarin Pharmaceutical (BMRN) to $104 From $98Here's Why - Bitget
Canaccord Lifts PT on BioMarin Pharmaceutical (BMRN) to $104 From $98 – Here’s Why - Yahoo Finance
Andra AP fonden Acquires 105,000 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
A Look At BioMarin (BMRN) Valuation After Recent Share Price Rebound And Undervaluation Debate - Sahm
Bernstein Lifts PT on BioMarin Pharmaceutical (BMRN) to $94 From $90, Here's Why - Bitget
Bernstein Lifts PT on BioMarin Pharmaceutical (BMRN) to $94 From $90, Here’s Why - Insider Monkey
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) - Yahoo Finance
Assessing BioMarin Pharmaceutical: Insights From 5 Financial Analysts - Sahm
BioMarin Pharmaceutical EVP Trades $381K In Company Stock - Benzinga
DNB Asset Management AS Acquires 154,954 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Beyond the Balance Sheet: What SWOT Reveals About BioMarin Pharm - GuruFocus
Friberg, Biomarin Pharmaceutical EVP, sells $381k in stock - Investing.com
Friberg, Biomarin Pharmaceutical EVP, sells $381k in stock By Investing.com - Investing.com Australia
Insider Selling: BioMarin Pharmaceutical (NASDAQ:BMRN) EVP Sells 6,326 Shares of Stock - MarketBeat
Davis, Biomarin Pharmaceutical EVP sells $1.6m in shares - Investing.com
Davis, Biomarin Pharmaceutical EVP sells $1.6m in shares By Investing.com - Investing.com South Africa
BioMarin (BMRN) legal chief sells shares and earns performance RSUs - Stock Titan
BioMarin Pharmaceutical (BMRN) CFO earns multiple performance-based stock awards - Stock Titan
Brokered sale notice for BioMarin (NASDAQ: BMRN) tied to vesting and ESPP - Stock Titan
BioMarin Pharmaceutical Inc. (BMRN) Seen as Attractive Buy Ahead of Transcon-CNP PDUFA, Says Wells Fargo - Yahoo Finance
BIOMARIN PHARMACEUTICAL INC SEC 10-K Report - TradingView
Fidelity proposes sale of BMRN shares (NASDAQ: BMRN) — Form 144 notice - Stock Titan
Canaccord raises BioMarin stock price target to $104 on earnings - Investing.com
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Primecap Management Co. CA - MarketBeat
H.C. Wainwright cuts BioMarin stock price target on competition By Investing.com - Investing.com South Africa
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2025 Earnings Call Transcript - Insider Monkey
BioMarin Reports Mixed Q4 Results with Earnings Miss - Intellectia AI
Sanford C. Bernstein Increases BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $94.00 - MarketBeat
Guggenheim Issues Pessimistic Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price - MarketBeat
Bernstein raises BioMarin stock price target on valuation outlook - Investing.com India
Bernstein raises BioMarin stock price target on valuation outlook By Investing.com - Investing.com South Africa
Is BioMarin Pharmaceutical (BMRN) Pricing Match Recent Share Rebound And DCF Upside Potential - Yahoo Finance
HC Wainwright Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $55.00 - MarketBeat
Biomarin Pharmaceutical Inc (BMRN) 財務データ
収益
当期純利益
現金流量
EPS
Biomarin Pharmaceutical Inc (BMRN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Davis George Eric | EVP, Chief Legal Officer |
Feb 26 '26 |
Sale |
61.36 |
26,061 |
1,599,103 |
72,453 |
4.35%
大文字化:
|
ボリューム (24 時間):